Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials

BACKGROUND: Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed. METHODS: A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernstein, David I., Cardin, Rhonda D., Pullum, Derek A., Bravo, Fernando J., Kousoulas, Konstantin G., Dixon, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436793/
https://www.ncbi.nlm.nih.gov/pubmed/30917165
http://dx.doi.org/10.1371/journal.pone.0213401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436793/
https://www.ncbi.nlm.nih.gov/pubmed/30917165
http://dx.doi.org/10.1371/journal.pone.0213401

Ejemplares similares